In trading on Monday, shares of NexPoint Real Estate Finance Inc's 8.50% Series A Cumulative Preferred Stock (Symbol: NREF.PRA) were yielding above the 9% mark based on its quarterly dividend (annualized to $2.125), with shares changing hands as low as $23.58 on the day. This compares to an average yield of 8.26% in the "Real Estate" preferred stock category, according to Preferred Stock Channel ....
In trading on Monday, shares of NexPoint Real Estate Finance Inc's 8.50% Series A Cumulative Preferred Stock (Symbol: NREF.PRA) were yielding above the 9% mark based on its quarterly dividend (annualized to $2.125), with shares changing hands as low as $23.58 on the day. This compares to an average yield of 8.26% in the "Real Estate" preferred stock category, according to Preferred Stock Channel . As of last close, NREF.PRA was trading at a 4.16% discount to its liquidation preference amount, versus the average discount of 16.37% in the "Real Estate" category. Below is a dividend history chart for NREF.PRA, showing historical dividend payments on NexPoint Real Estate Finance Inc's 8.50% Series A Cumulative Preferred Stock: In Monday trading, NexPoint Real Estate Finance Inc's 8.50% Series A Cumulative Preferred Stock (Symbol: NREF.PRA) is currently off about 0.9% on the day, while the common shares (Symbol: NREF) are up about 1.2%. Click here to find out the 50 highest yielding preferreds » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Monday, shares of Morgan Stanley's Floating Rate Non-Cumulative Preferred Stock, Series A (Symbol: MS.PRA) were yielding above the 6% mark based on its quarterly dividend (annualized to $1.1585), with shares changing hands as low as $19.24 on the day. This compares to an average yield of 6.62% in the "Financial" preferred stock category, according to Preferred Stock Channel . As of l...
In trading on Monday, shares of Morgan Stanley's Floating Rate Non-Cumulative Preferred Stock, Series A (Symbol: MS.PRA) were yielding above the 6% mark based on its quarterly dividend (annualized to $1.1585), with shares changing hands as low as $19.24 on the day. This compares to an average yield of 6.62% in the "Financial" preferred stock category, according to Preferred Stock Channel . As of last close, MS.PRA was trading at a 22.60% discount to its liquidation preference amount, versus the average discount of 12.44% in the "Financial" category. Investors should keep in mind that the shares are not, meaning that in the event of a missed payment, the company does not have to pay the balance of missed dividends to preferred shareholders before resuming a common dividend. Below is a dividend history chart for MS.PRA, showing historical dividend payments on Morgan Stanley's Floating Rate Non-Cumulative Preferred Stock, Series A: In Monday trading, Morgan Stanley's Floating Rate Non-Cumulative Preferred Stock, Series A (Symbol: MS.PRA) is currently off about 0.5% on the day, while the common shares (Symbol: MS) are up about 2.8%. Click here to find out the 50 highest yielding preferreds » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
CBS News, the BBC's US partner, reported a flight attendant was found alive and strapped into her seat, which was outside of the plane, after it fell through a hole in the floor of the aircraft during the crash. She's said to have serious but non-life threatening injuries.
CBS News, the BBC's US partner, reported a flight attendant was found alive and strapped into her seat, which was outside of the plane, after it fell through a hole in the floor of the aircraft during the crash. She's said to have serious but non-life threatening injuries.
Looking at the universe of stocks we cover at Dividend Channel , in trading on Monday, shares of Devon Energy Corp. (Symbol: DVN) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $46.80 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a cons...
Looking at the universe of stocks we cover at Dividend Channel , in trading on Monday, shares of Devon Energy Corp. (Symbol: DVN) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $46.80 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF (SPY) back on 12/31/1999 — you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Devon Energy Corp. (Symbol: DVN) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Devon Energy Corp., looking at the history chart for DVN below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. Click here to find out which 9 other dividend stocks just recently went on sale » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
On March 18, 2026, Chief Strategy Officer Gregory Sorensen reported the sale of 15,000 shares of RadNet (RDNT +0.29%) in multiple open-market transactions, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 15,000 Shares withheld (direct) 5,919 Shares traded (direct) 20,919 Transaction value ~$932,000 Post-transaction shares (direct) 1,223,923 Post-transaction ...
On March 18, 2026, Chief Strategy Officer Gregory Sorensen reported the sale of 15,000 shares of RadNet (RDNT +0.29%) in multiple open-market transactions, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 15,000 Shares withheld (direct) 5,919 Shares traded (direct) 20,919 Transaction value ~$932,000 Post-transaction shares (direct) 1,223,923 Post-transaction value (direct ownership) ~$75.87 million Transaction value based on SEC Form 4 weighted average purchase price ($62.12); post-transaction value based on March 18, 2026 market close. Key questions How does the scale of this sale compare to prior open-market transactions by Sorensen? The 15,000-share sale is the only open-market sale in the last nine months. He previously sold 100,000 shares last May. The 15,000-share sale is the only open-market sale in the last nine months. He previously sold 100,000 shares last May. What is the impact of this transaction on direct ownership? Direct holdings declined by 1.21%, leaving 1,223,923 shares directly owned. Direct holdings declined by 1.21%, leaving 1,223,923 shares directly owned. Were any derivative securities or indirect entities involved in this transaction? No, the transaction involved only direct holdings of common stock; no options, warrants, or indirect entities such as trusts or LLCs were utilized. No, the transaction involved only direct holdings of common stock; no options, warrants, or indirect entities such as trusts or LLCs were utilized. Does the sale timing coincide with changes in RadNet's stock price or major company events? The transaction occurred as RadNet shares closed at $61.99 on March 18, 2026, with a 24.85% one-year total return as of that date. Company overview Metric Value Market capitalization $4.77 billion Revenue (TTM) $2.04 billion Net income (TTM) ($18.65 million) 1-year price change 24.85% * 1-year price change calculated using March 18, 2026 as the reference date. Company snapshot RadNet provides...
Blackrock CEO Larry Fink speaks on the set of CNBC on the floor of the New York Stock Exchange (NYSE) on April 11, 2025, in New York City. Timothy A. Clary | Afp | Getty Images More than 70 million Americans — including retirees, disabled individuals and families — rely on Social Security benefits for monthly income. It's "one of the most effective poverty-prevention programs in history," BlackRoc...
Blackrock CEO Larry Fink speaks on the set of CNBC on the floor of the New York Stock Exchange (NYSE) on April 11, 2025, in New York City. Timothy A. Clary | Afp | Getty Images More than 70 million Americans — including retirees, disabled individuals and families — rely on Social Security benefits for monthly income. It's "one of the most effective poverty-prevention programs in history," BlackRock CEO Larry Fink wrote in his annual chairman's letter to investors, released Monday. Social Security keeps an estimated 29 million Americans out of poverty each year, Fink wrote, citing Census data. Even with that "extraordinary achievement," the 90-year old program could be improved, according to Fink. "The issue is: Social Security provides stability, but it doesn't allow most Americans to build wealth in a way that grows with their country," Fink wrote. Fink has called for investing on behalf of Social Security As a pay-as-you-go program, Social Security is largely funded by payroll taxes . Both employers and employees contribute 6.2% toward the program, while self-employed individuals pay 12.4% on earnings up to $184,500 in 2026. Money not immediately used to pay benefits is deposited into Social Security's trust funds, which are invested in U.S. Treasury bonds. The combined retirement and disability trust funds earned a 2.6% annual effective interest rate in 2025, according to Social Security Administration data. Meanwhile, the stock market saw substantial gains last year, with the S&P 500 up about 16% . A 60/40 portfolio of stocks and bonds was up nearly 15% for 2025, based on the performance of the Morningstar US Moderate Target Allocation Index. Read more CNBC personal finance coverage BlackRock CEO Fink: Trump accounts may be 'significant' wealth-building tool The uneven cost of tariffs: Why some households will pay more than others When it comes to private credit, 'some caution is reasonable,' advisor says 'War tax resistance' gains attention amid Iran conflict, ...
weerapatkiatdumrong/iStock via Getty Images Key Takeaways Markets: Growth stock momentum saw a reversal in the fourth quarter as concerns over elevated technology company valuations and aggressive artificial intelligence (AI) capex commitments caused the benchmark Russell 1000 Growth Index (RLG) to advance just 1.1%, trailing the Russell 1000 Value Index by 270 basis points. For the full year, how...
weerapatkiatdumrong/iStock via Getty Images Key Takeaways Markets: Growth stock momentum saw a reversal in the fourth quarter as concerns over elevated technology company valuations and aggressive artificial intelligence (AI) capex commitments caused the benchmark Russell 1000 Growth Index (RLG) to advance just 1.1%, trailing the Russell 1000 Value Index by 270 basis points. For the full year, however, large cap growth stocks maintained market leadership due to positive AI sentiment and continued strong earnings growth from mega cap companies, enabling the RLG to finish up 18.6%. Contributors: Intuitive Surgical ( ISRG ), Thermo Fisher Scientific ( TMO ), Vertex Pharmaceuticals ( VRTX ) and ASML ( ASML ). Stock selection in consumer discretionary. Detractors: Netflix ( NFLX ), Eaton ( ETN ), Meta Platforms ( META ), underweight to Alphabet ( GOOG ) and not holding Eli Lilly ( LLY ). Stock selection in communication services and information technology (IT). Outlook: We believe resurgent growth in the economy ex-tech in 2026 from fiscal stimulus and easing monetary policy should support broadening participation within our growth universe. Performance Review The Fund underperformed in the fourth quarter and ended the year trailing our concentrated benchmark by approximately 900 bps (gross of fees). The majority of the underperformance can be attributed to our differentiated AI and mega cap positioning compared to the benchmark, with poor stock selection in health care the second-largest detractor. Netflix fell due to investor uncertainty and concerns over its proposed $72 billion acquisition of Warner Bros. Discovery's studio assets, a move complicated by a rival bid from Paramount/Skydance, potential regulatory hurdles, and integration risks, muddling its previously clear growth narrative. Eaton declined as the company acknowledged near-term headwinds that caused it to lower 2026 guidance below consensus forecasts but reiterated that the long-term demand outlook for i...
As tensions rise in Iran, energy stocks are in the spotlight. The ongoing conflict has led to disruptions in the Strait of Hormuz, consequently driving oil and gas prices upward. Against this backdrop, investors may be seeking exposure to energy stocks. For those new to the market, fractional shares make it easier than ever to invest, allowing you to gain exposure to top stocks with as little as $...
As tensions rise in Iran, energy stocks are in the spotlight. The ongoing conflict has led to disruptions in the Strait of Hormuz, consequently driving oil and gas prices upward. Against this backdrop, investors may be seeking exposure to energy stocks. For those new to the market, fractional shares make it easier than ever to invest, allowing you to gain exposure to top stocks with as little as $100. If you're considering adding energy stocks to your portfolio, here are three smart energy stocks to buy today. ExxonMobil's low-cost, high-return assets provide upside amid high prices ExxonMobil (XOM +0.40%) runs one of the largest integrated oil and gas companies in the world. The oil and gas giant holds key assets across Guyana, the Permian Basin, and key LNG terminals, giving it a strong platform to support ongoing energy production and generate recurring revenue. Its integrated business model provides upstream and downstream exposure, giving it stability in the highly volatile oil and gas sectors. In recent years, Exxon has aggressively shifted to advantaged assets, which boast low production costs and high returns. By 2030, these assets are projected to account for 65% of its upstream production, up from 59% in 2025. It is also leveraging technology, such as what it calls cube development and lightweight proppants, to maximize well performance and improve drilling efficiency. Expand NYSE : XOM ExxonMobil Today's Change ( 0.40 %) $ 0.64 Current Price $ 160.31 Key Data Points Market Cap $665B Day's Range $ 155.11 - $ 161.42 52wk Range $ 97.80 - $ 162.44 Volume 979K Avg Vol 21M Gross Margin 21.56 % Dividend Yield 2.53 % The ongoing conflict in Iran affects Exxon in a few ways. For one, TD Cowen estimates that 60% of its liquefied natural gas (LNG) business is based in the Middle East, and Iranian strikes have affected some of its infrastructure there. On the flip side, with Brent crude oil surging past $100, the company's low-cost production in the Permian and Guyan...
Key Points ExxonMobil boasts low-cost, high-return assets in Guyana and the Permian Basin. SLB provides essential technology and services for oil and gas exploration. Enterprise Products Partners generates stable, fee-based revenue, making it less vulnerable to fluctuating oil and gas prices. 10 stocks we like better than ExxonMobil › As tensions rise in Iran, energy stocks are in the spotlight. T...
Key Points ExxonMobil boasts low-cost, high-return assets in Guyana and the Permian Basin. SLB provides essential technology and services for oil and gas exploration. Enterprise Products Partners generates stable, fee-based revenue, making it less vulnerable to fluctuating oil and gas prices. 10 stocks we like better than ExxonMobil › As tensions rise in Iran, energy stocks are in the spotlight. The ongoing conflict has led to disruptions in the Strait of Hormuz, consequently driving oil and gas prices upward. Against this backdrop, investors may be seeking exposure to energy stocks. For those new to the market, fractional shares make it easier than ever to invest, allowing you to gain exposure to top stocks with as little as $100. If you're considering adding energy stocks to your portfolio, here are three smart energy stocks to buy today. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » ExxonMobil's low-cost, high-return assets provide upside amid high prices ExxonMobil (NYSE: XOM) runs one of the largest integrated oil and gas companies in the world. The oil and gas giant holds key assets across Guyana, the Permian Basin, and key LNG terminals, giving it a strong platform to support ongoing energy production and generate recurring revenue. Its integrated business model provides upstream and downstream exposure, giving it stability in the highly volatile oil and gas sectors. In recent years, Exxon has aggressively shifted to advantaged assets, which boast low production costs and high returns. By 2030, these assets are projected to account for 65% of its upstream production, up from 59% in 2025. It is also leveraging technology, such as what it calls cube development and lightweight proppants, to maximize well performance and improve drilling efficiency. The ongoing conflict in Iran affects Exxon...
Nineteen-year-old boxer Isis Sio was placed into a medically induced coma after a knockout loss to Jocelyn Camarillo on Saturday in San Bernardino, California, ProBoxTV announced after broadcasting the fight. Sio, who entered with a 1-2 professional record, was knocked out by a series of punches 78 seconds into the fight, the opener of the night’s card. She was convulsing in the ring after the kno...
Nineteen-year-old boxer Isis Sio was placed into a medically induced coma after a knockout loss to Jocelyn Camarillo on Saturday in San Bernardino, California, ProBoxTV announced after broadcasting the fight. Sio, who entered with a 1-2 professional record, was knocked out by a series of punches 78 seconds into the fight, the opener of the night’s card. She was convulsing in the ring after the knockout and transported to Loma Linda University Health, where she was placed into the coma. “On behalf of CEO Garry Jonas and the entire ProBox family, we are praying for a speedy recovery for Isis Sio,” read a ProBoxTV statement. “Ms Sio is currently in a medically induced coma. Our thoughts are with her and her family at this very difficult time. Please join us in wishing for a full recovery.” Sio, who is from North Dakota, was fighting at 107.5lbs in the junior flyweight division, down from 114lbs and 118lbs in her previous two bouts. Camarillo, a three-time amateur national champion, entered with a 5-0 record with all her previous wins by decision. “Nothing but respect. keeping her in my prayers and wishing her healing and a full recovery,” Camarillo wrote on Instagram after the fight. Sio is North Dakota’s only active female boxer. She also lost her previous fight by knockout after taking a series of heavy body blows.
Bank of America’s latest Asia supply chain checks suggest Apple Inc (NASDAQ:AAPL, XETRA:APC) is preparing to introduce its first foldable iPhone in 2026, as the firm reiterated its ‘Buy’ rating while modestly lowering its price objective to $320 from $325. Shares traded hands at $252 on...
Bank of America’s latest Asia supply chain checks suggest Apple Inc (NASDAQ:AAPL, XETRA:APC) is preparing to introduce its first foldable iPhone in 2026, as the firm reiterated its ‘Buy’ rating while modestly lowering its price objective to $320 from $325. Shares traded hands at $252 on...
Cantor Fitzgerald has downgraded Gossamer Bio ( GOSS ) to neutral from overweight citing uncertainty in the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension. The investment bank's decision comes after topline results released in February from the phase 3 PROSERA study were a disappointment after the primary endpoint did not meet statistical significance. Gossamer ...
Cantor Fitzgerald has downgraded Gossamer Bio ( GOSS ) to neutral from overweight citing uncertainty in the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension. The investment bank's decision comes after topline results released in February from the phase 3 PROSERA study were a disappointment after the primary endpoint did not meet statistical significance. Gossamer "does have some compelling data, and the drug clearly shows a solid signal," wrote analyst Olivia Brayer Saunders. "But it's hard for us to get any level of conviction in whether they have a strong case for a path to commercialization." The company has asked for a Type C meeting with the US FDA that should come in June. Saunders added that will likely mean clarity on seralutinib's path forward in July. More on Gossamer Bio Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension - Slideshow Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript Small-Cap healthcare stocks ranked by quant ratings after earnings season Seeking Alpha’s Quant Rating on Gossamer Bio Historical earnings data for Gossamer Bio
Iran's denial of talks with US negotiators are likely the Iranian government not wanting to 'project any sign of weakness' to their public, says Blomberg's Onur Ant. Speaking in Memphis, President Trump said that there's a 'very good chance' of ending up with a deal, while Iran's government solidly denied any contact was taking place. (Source: Bloomberg)
Iran's denial of talks with US negotiators are likely the Iranian government not wanting to 'project any sign of weakness' to their public, says Blomberg's Onur Ant. Speaking in Memphis, President Trump said that there's a 'very good chance' of ending up with a deal, while Iran's government solidly denied any contact was taking place. (Source: Bloomberg)
The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in revenue. The race is one for companies to get to the market as quickly as possible with an approved treatment. One stock that is in the thick of things right now is Viking Therapeutics (VKTX +1.64%). Although...
The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in revenue. The race is one for companies to get to the market as quickly as possible with an approved treatment. One stock that is in the thick of things right now is Viking Therapeutics (VKTX +1.64%). Although it doesn't have an approved drug just yet, it's moving in the right direction. And if it's successful, its shares could skyrocket. But even before it might obtain approval for its key drug, VK2735, there could be a catalyst that gives the healthcare stock a near-term boost, as the company could soon release data from a key clinical trial. VK2735 could be used for maintenance dosing Viking says that "based on exciting early data," the company recently initiated a study to assess the possibility of VK2735 being used as a maintenance dose. It's being tested as a monthly injection, and also as a weekly and daily oral medication. The company says it expects to announce the results in the third quarter of this year. If they're promising, that could give the stock a significant boost. It could open up the possibility for VK2735 to more easily take market share from bigger GLP-1 players in the market, especially if it offers patients a competitive price point. Rather than simply starting on VK2735, patients who have already achieved significant weight loss could potentially seek out VK2735 for maintenance purposes. Expand NASDAQ : VKTX Viking Therapeutics Today's Change ( 1.64 %) $ 0.53 Current Price $ 32.86 Key Data Points Market Cap $3.7B Day's Range $ 32.43 - $ 33.54 52wk Range $ 18.92 - $ 43.15 Volume 54K Avg Vol 3M Is Viking Therapeutics stock a good buy in 2026? It has been an underwhelming start to 2026 for Viking Therapeutics. The stock is down 6% thus far, and it has declined 24% from its 52-week high of $43.15. The company doesn't generate any revenue today, and the hope...
Key Points Viking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials. The company is evaluating whether it can be taken monthly for maintenance dosing. 10 stocks we like better than Viking Therapeutics › The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to bi...
Key Points Viking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials. The company is evaluating whether it can be taken monthly for maintenance dosing. 10 stocks we like better than Viking Therapeutics › The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in revenue. The race is one for companies to get to the market as quickly as possible with an approved treatment. One stock that is in the thick of things right now is Viking Therapeutics (NASDAQ: VKTX). Although it doesn't have an approved drug just yet, it's moving in the right direction. And if it's successful, its shares could skyrocket. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » But even before it might obtain approval for its key drug, VK2735, there could be a catalyst that gives the healthcare stock a near-term boost, as the company could soon release data from a key clinical trial. VK2735 could be used for maintenance dosing Viking says that "based on exciting early data," the company recently initiated a study to assess the possibility of VK2735 being used as a maintenance dose. It's being tested as a monthly injection, and also as a weekly and daily oral medication. The company says it expects to announce the results in the third quarter of this year. If they're promising, that could give the stock a significant boost. It could open up the possibility for VK2735 to more easily take market share from bigger GLP-1 players in the market, especially if it offers patients a competitive price point. Rather than simply starting on VK2735, patients who have already achieved significant weight loss could potentially seek out VK2735 for maintenance purposes. Is Viking Therapeutics s...
Stockyme/iStock via Getty Images By Elior Manier Another week, another absolutely chaotic session all across the market board. This morning came with some much better news for the conflict. US-Iran talks are picking up for the first time since the end of February, and that's creating a crazy shift in markets, to say the least. After another gap above $100 per barrel in WTI ( CL1:COM ) at the Globe...
Stockyme/iStock via Getty Images By Elior Manier Another week, another absolutely chaotic session all across the market board. This morning came with some much better news for the conflict. US-Iran talks are picking up for the first time since the end of February, and that's creating a crazy shift in markets, to say the least. After another gap above $100 per barrel in WTI ( CL1:COM ) at the Globex open, oil prices have been tumbling to lows not seen since March 11. WTI Oil 1H Chart - March 23, 2026 (Source: TradingView) WTI is down around 12% on the session, back to ~$88 after the news. Brent ( CO1:COM ) is also back below $100 for the first time since March 13. The conflict isn't going to end suddenly, but this marks a flashy cooling in tensions, especially after recent fears of escalation over the weekend, with Saudi Arabia expressing heavy discontent with the latest Iranian attacks on Riyadh. The US also threatened to strike power plants in Iran as retaliation for the continued pressure on the Strait of Hormuz. The deadline for such is Monday evening, but this could now be averted. This culminated in a re-start of talks between the US and Iran, as announced by President Trump in a morning Truth Social post and public address , and led to waves of crazy swings around all asset classes. Gold dove to $4,100, now bouncing higher Gold 2H Chart - March 23, 2026 (Source: TradingView) Gold ( XAUUSD:CUR ), along with the entire metals space, has been subject to wild volatility throughout the past weeks. After failing to regain its early-2026 $5,600 record despite the conflict, large profit-taking culminated in a significant price tumble of close to 25% to $4,101. It did rebound sharply back to around $4,400, a key momentum level for upcoming action (neutral/bullish above, bearish below). The culprit was the renewed inflationary fears that dragged global assets lower. But those are significantly easing as we speak, with the recent moves in energy commodities. Current Sess...
Brazilian Lawmaker Wears Blackface To Mock Transgenderism Authored by Ben Sellers via Headline USA , A Brazilian legislator last week mocked one of LGBT activists’ core arguments in favor of transgenderism with a simple demonstration during a state assembly session in São Paulo. Faviana Bolsonaro, a 32-year-old female member of the country’s right-leaning Liberal Party, took the dais on Wednesday ...
Brazilian Lawmaker Wears Blackface To Mock Transgenderism Authored by Ben Sellers via Headline USA , A Brazilian legislator last week mocked one of LGBT activists’ core arguments in favor of transgenderism with a simple demonstration during a state assembly session in São Paulo. Faviana Bolsonaro, a 32-year-old female member of the country’s right-leaning Liberal Party, took the dais on Wednesday to protest the appointment of Erika Hilton, a biological-male transgender activist, to the Chamber of Deputies, equivalent to the U.S. House of Representatives. Hilton, who is black, is a member of the opposing Socialism and Liberty Party. A viral video showed that Bolsonaro (who changed her name in solidarity with former conservative president Jair Bolsonaro , no relation) applied blackface during her speech to underscore the point that wishful thinking could not change one’s inherent identity. “I am a white woman. I’ve had the privileges of a white person my whole life,” she said, according to a translation from the original Portuguese. “Now, at 32, I decide to paint myself, to disguise myself as a black person … and I ask you: did I become black? Do I feel the pain that black people have suffered? … No.” This post is misleading, not because you must agree with Fabiana Bolsonaro, but because it distorts what she actually said. Here are her own words, translated as faithfully as possible: “I am a white woman. I’ve had the privileges of a white person my whole life.” “Now, at… — Jose Alfredo 🇧🇷🔺 (@josealfredobh) March 20, 2026 Biographical details are unclear as to when and if Hilton fully transitioned to “female,” although reports suggest that the former sex worker has been living as a woman since at least 2015, when Hilton’s LGBT activism first rose to prominence. Hilton and another transgender legislator, Duda Salabert, both entered the national parliament following Brazil’s highly controversial 2022 election, the equivalent of the 2020 election in the U.S., in which far...
FinancialContent - Accepted into Advanced Micro Devices ($AMD) AI Developer Program to Accelerate LLM Training and Inference : Avalon GloboCare Corp. (Nasdaq: ALBT) FinancialContent
FinancialContent - Accepted into Advanced Micro Devices ($AMD) AI Developer Program to Accelerate LLM Training and Inference : Avalon GloboCare Corp. (Nasdaq: ALBT) FinancialContent